COVID 19 is a disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infects the human host cells through the ACE2 receptors. One of the concerns with
the disease is the fact that it causes acute myocardial injury and chronic damage to the
cardiovascular system. The condition is spreading at a high rate, and it has been the cause of
mortality, mostly among people with co-morbidities (Zheng et al., 2020). An outbreak of
Pneumonia caused by a novel coronavirus occurred in Wuhan, Hubei province in December,
and it spread rapidly through China then become a global pandemic. The disease is superiorly
infectious and has infected people worldwide. It is, therefore, a problem that should be dealt
with in the best way possible to protect the lives of the people in the society. The disease
spreads through contact, and the attempts to contain it have failed; hence it is important to
find ways of preventing the infection and treatment of the infected persons in the society
(Zheng et al., 2020). In the patients with COVID 19, hydroxychloroquine (200mg every 12
hours) compared to a placebo, decreases mortality in one week. Singh et al., (2020)
conducted a study that was aimed at reviewing the available literature and relevant websites
that talk about the use of chloroquin and hydroxychlorouin, the side effects that are related to
the drugs and the guidelines that have been put in place about its use. The outcome measures
in the research included the number of recoveries and the number of mortalities. They found
out that two small human studies have been conducted with both these drugs in COVID-19,
and have shown significant improvement in some parameters in patients with COVID-19.
References
Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020). Chloroquine and
hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A
systematic search and a narrative review with a special reference to India and other
COVID 19 ASSIGNMENT 3
developing countries. Diabetes & Metabolic Syndrome: Clinical Research &
Reviews, 14(3), 241-246. https://doi.org/10.1016/j.dsx.2020.03.011
Zheng, Y., Ma, Y., Zhang, J., & Xie, X. (2020). undefined. Nature Reviews
Cardiology, 17(5), 259-260. https://doi.org/10.1038/s41569-020-0360-5